Chief Executive Officer

Dr. Cutler, CEO of Worldwide Clinical Trials (WCT), has a proven track record. He was founder and chairman of Worldwide Clinical Trials, Inc. (“Old WCT”), a global CRO providing a full range of product development services on a global basis to the pharmaceutical and biotechnology industries from 1986-1999, which was successfully merged into another CRO. In addition, he was founder and director of California Clinical Trials, one of the largest Phase I-III clinical pharmacology and investigational sites in the U.S. From 2000 to 2006, he founded and served as president and CEO of Alamo Pharmaceuticals, LLC.

Dr. Cutler is a board-certified psychiatrist and is also board-qualified in both neurology and clinical pharmacology. He was active at the National Institutes of Health (NIH) for over nine years in a variety of positions, such as deputy clinical director of the National Institute on Aging and chief, Section on Brain Aging and Dementia. Currently, he is president of the American Foundation for Clinical Pharmacology and serves on a special emphasis panel review committee for the National Institute on Aging for NIH. Dr. Cutler has been invited to give several hundred international and national presentations in the areas of aging, clinical pharmacology and drug development and has authored over 261 publications, including nine books on the topics of clinical pharmacology, aging, Alzheimer’s disease, schizophrenia, anxiety disorders and diabetes.

Dr. Cutler has also been instrumental in the design and clinical development of nearly 200 compounds in numerous therapeutic areas and has particular expertise in central nervous system disorders. His development of the revolutionary dynabridge study methodology has made feasible the study of both the presence and the dynamic activity of a compound in the brain and has facilitated the rapid and effective development of a number of compounds. Dr. Cutler also developed and obtained a FDA-approved registration, as well as marketed a new drug product to treat schizophrenia, FazaClo®. In gaining approval for FazaClo®, the protocol designed by Dr. Cutler changed the approval process for generic formulations of similar CNS drugs requiring testing in patients consistent with the FazaClo® study. Dr. Cutler earned an M.D. from St. Louis University Medical School and a B.A. from St. Louis University.